Biotech News
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
GSK & GEN announced submission of BLA to the FD) for Arzerra to treat patients whose CLL is resistant (refractory) to previous therapies.
